Two-drug versus three-drug induction chemotherapy in pediatric acute myeloid leukemia: a randomized controlled trial

The benefit of three-drug induction chemotherapy over a two-drug induction has not been evaluated in pediatric acute myeloid leukemia (AML). We, therefore, conducted a randomized controlled trial to ascertain the benefit of a three-drug induction regimen. Patients aged 1–18 years with newly diagnose...

Descripción completa

Detalles Bibliográficos
Autores principales: Radhakrishnan, Venkatraman, Bakhshi, Sameer, Kayal, Smita, Thampy, Cherian, Batra, Ankit, Shenoy, Praveen Kumar, Kumar, Hemanth, Rajaraman, Swaminathan, Chaudhary, Shilpi, Bisht, Reema, Dubashi, Biswajit, Ganesan, Trivadi S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9444698/
https://www.ncbi.nlm.nih.gov/pubmed/36068213
http://dx.doi.org/10.1038/s41408-022-00726-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9444698/
https://www.ncbi.nlm.nih.gov/pubmed/36068213
http://dx.doi.org/10.1038/s41408-022-00726-1

Ejemplares similares